EFFECTOR Therapeutics Cash Flow From Operations vs. Beta

EFTRWDelisted Stock  USD 0  0.00  0.00%   
Based on EFFECTOR Therapeutics' profitability indicators, EFFECTOR Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess EFFECTOR Therapeutics' ability to earn profits and add value for shareholders.
For EFFECTOR Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of EFFECTOR Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well EFFECTOR Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between EFFECTOR Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of EFFECTOR Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Please note, there is a significant difference between EFFECTOR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if EFFECTOR Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EFFECTOR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

EFFECTOR Therapeutics Beta vs. Cash Flow From Operations Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining EFFECTOR Therapeutics's current stock value. Our valuation model uses many indicators to compare EFFECTOR Therapeutics value to that of its competitors to determine the firm's financial worth.
EFFECTOR Therapeutics is rated # 4 in cash flow from operations category among its peers. It also is rated # 4 in beta category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the EFFECTOR Therapeutics' earnings, one of the primary drivers of an investment's value.

EFFECTOR Beta vs. Cash Flow From Operations

Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

EFFECTOR Therapeutics

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(29.55 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

EFFECTOR Therapeutics

Beta

 = 

Covariance

Variance

 = 
0.62
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

EFFECTOR Beta Comparison

EFFECTOR Therapeutics is currently under evaluation in beta category among its peers.

Beta Analysis

As returns on the market increase, EFFECTOR Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding EFFECTOR Therapeutics is expected to be smaller as well.

EFFECTOR Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on EFFECTOR Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of EFFECTOR Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the EFFECTOR Therapeutics' important profitability drivers and their relationship over time.

Use EFFECTOR Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if EFFECTOR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EFFECTOR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

EFFECTOR Therapeutics Pair Trading

EFFECTOR Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to EFFECTOR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace EFFECTOR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back EFFECTOR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling EFFECTOR Therapeutics to buy it.
The correlation of EFFECTOR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as EFFECTOR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if EFFECTOR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for EFFECTOR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your EFFECTOR Therapeutics position

In addition to having EFFECTOR Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Printing and Publishing Thematic Idea Now

Printing and Publishing
Printing and Publishing Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Printing and Publishing theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Printing and Publishing Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Consideration for investing in EFFECTOR Pink Sheet

If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings